Abstract: The present Invention relates to a pellet comprising melatonin and methods of treating insomnia.

Abstract: A computer implemented method for supporting the treatment of insomnia with melatonin. The method includes receiving sleep data relating to a patient; determining a dosage time for the patient to take a dose of the melatonin based on the sleep data; and indicating the dosage time.

Abstract: A method for treating obesity in a patient, the method comprising administering a dose of a GLP1 agonist to the patient in a treatment regimen effective to manage the patient's satiety and thereby effect a reduction in the patient's weight; and, in conjunction with the administration of the dose of GLP1 agonist, engaging in a directed digital therapeutic program that manages patient weight loss and the treatment regimen for the GLP1 agonist with the objective of achieving a predetermined target weight for the patient, wherein the patient achieves the target weight.

Abstract: A compact, low-power, high image rejection sideband separation receiver is provided. The receiver observes an input radio frequency (RF) signal of multiple spectral lines (spectral observation), then downconverts the signals to intermediate frequency (IF), and then separates the signals to be observed simultaneously in multiple channels. An embodiment is used to observe a signal (G-band) with two spectral lines and utilizes a two stage Weaver architecture to downconvert the signal's frequency, including a combination of mixers in the second stage that achieves the separation of two different channels.

Abstract: The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

Abstract: There is a dosage regimen for amlodipine for use in the treatment of hypertension.

Abstract: A compact, low-power, high image rejection sideband separation receiver is provided. The receiver observes an input radio frequency (RF) signal of multiple spectral lines (spectral observation), then downconverts the signals to intermediate frequency (IF), and then separates the signals to be observed simultaneously in multiple channels. An embodiment is used to observe a signal (G-band) with two spectral lines and utilizes a two stage Weaver architecture to downconvert the signal's frequency, including a combination of mixers in the second stage that achieves the separation of two different channels.

Abstract: A method of producing an intermediate program representation for an executable personalised medicine treatment program, comprising: providing a domain specific language environment comprising a personalised-medicine programming language syntax and a user interface; selecting a medical knowledge database for a medical condition; receiving user input to build, using the personalised-medicine programming language syntax and the medical knowledge database, a treatment package for implementing one or more treatment modalities for the medical condition, the treatment package including: treatment objectives defining terminating conditions of the one or more treatment modalities; safety guardrails for ensuring patient safety; and treatment titration definitions for modulating the one or more treatment modalities; and validating the treatment package to demonstrate that the treatment objectives, safety guardrails and treatment titration definitions will be satisfied during execution of the personalised medicine treatm

Abstract: The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

Abstract: The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

Abstract: The present disclosure relates to monitoring patient compliance with a dosage regimen. In some aspects, a patient unique identifier, which enables a patient to be uniquely identified and associated with a patient record, is received. A message is received. The message includes a package unique identifier that enables a package that a drug administered to the patient was stored within to be uniquely identified. The message includes at least one pair of values, wherein each pair of values corresponds to an administration event and indicates an amount of the drug administered to the patient and a time of administration of the amount of the drug to the patient. The drug administered to the patient using the package unique identifier is identified. The identity of the drug and the at least one pair of values are stored against the patient record, which includes a dosage regimen associated with the patient.

Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.

Abstract: A method, system, and apparatus for positioning a patient. A set of arm positioning sleeves is provided. Each arm positioning sleeve in the set of arm positioning sleeves is wrapped around a portion of an arm of a user lying on an operating table. One end of each body strap in a set of body straps is connected to a set of rails of the operating table. A set of body strap fasteners is provided that includes a set of hook-and-loop fastener material strips attached to an inner surface of each body strap. An opposing set of hook-and-loop material strips is attached to a portion of an outer surface of each arm positioning sleeve. The set of opposing hook-and-loop material strips on the set of arm positioning sleeves fastens to the set of hook-and-loop fastener material strips on the set of body straps to secure each arm of the user lying on the operating table in a desired position.

Abstract: An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of sialorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.

Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.

Abstract: A method, system, and apparatus for positioning a patient. A set of arm positioning sleeves is provided. Each arm positioning sleeve in the set of arm positioning sleeves is wrapped around a portion of an arm of a user lying on an operating table. One end of each body strap in a set of body straps is connected to a set of rails of the operating table. A set of body strap fasteners is provided that includes a set of hook-and-loop fastener material strips attached to an inner surface of each body strap. An opposing set of hook-and-loop material strips is attached to a portion of an outer surface of each arm positioning sleeve. The set of opposing hook-and-loop material strips on the set of arm positioning sleeves fastens to the set of hook-and-loop fastener material strips on the set of body straps to secure each arm of the user lying on the operating table in a desired position.